Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

[1]  H. Thiele,et al.  The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[2]  K. Bailey,et al.  Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. , 2020, JAMA.

[3]  M. Price,et al.  Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.

[4]  H. Glick,et al.  Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention , 2020, Circulation. Genomic and precision medicine.

[5]  Xiang Ma,et al.  Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[6]  M. Postma,et al.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. , 2019, The New England journal of medicine.

[7]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[8]  Marco Valgimigli,et al.  Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. , 2019, JACC. Cardiovascular interventions.

[9]  S. Donegan,et al.  Clinical Epidemiology and Global Health , 2022 .

[10]  G. Levine,et al.  ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. , 2018, Journal of the American College of Cardiology.

[11]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[12]  Diego Ardissino,et al.  Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial. , 2018, Journal of the American College of Cardiology.

[13]  J. Moon,et al.  Role of genetic testing in patients undergoing percutaneous coronary intervention , 2018, Expert review of clinical pharmacology.

[14]  Deepak L. Bhatt,et al.  International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies , 2017, Circulation.

[15]  Seung‐Jung Park,et al.  Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial. , 2017, The American journal of cardiology.

[16]  D. Angiolillo.  Dual antiplatelet therapy guided by platelet function testing , 2017, The Lancet.

[17]  M. Hadamitzky,et al.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial , 2017, The Lancet.

[18]  C. Dávila-Fajardo,et al.  Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. , 2016, International journal of cardiology.

[19]  E. Vicaut,et al.  Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial , 2016, The Lancet.

[20]  Bo Wang,et al.  Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population , 2016, Journal of cardiovascular pharmacology.

[21]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[22]  Ya‐Ling Han,et al.  Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study , 2015, Journal of geriatric cardiology : JGC.

[23]  D. Angiolillo,et al.  Platelet Function Testing in Contemporary Clinical and Interventional Practice , 2014, Current Treatment Options in Cardiovascular Medicine.

[24]  Xiang Ma,et al.  Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. , 2013, International journal of cardiology.

[25]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[26]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[27]  D. Aradi,et al.  Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention , 2012, Journal of Thrombosis and Thrombolysis.

[28]  A. Hingorani,et al.  CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. , 2011, Journal of the American Medical Association (JAMA).

[29]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[30]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[31]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[32]  B. J. Barratt,et al.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.

[33]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[34]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[35]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[36]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.